These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 12403377

  • 1. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT.
    Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 03; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 5. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Apr 03; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 03; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 7. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Feb 03; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 03; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 9. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.
    Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, De Nisco A, Angelone DF, Compagnone A, Delogu AB.
    Rheumatol Int; 2010 Apr 03; 30(6):841-6. PubMed ID: 20049445
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 03; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 11. Kawasaki disease: Medical therapies.
    Newburger JW.
    Congenit Heart Dis; 2017 Sep 03; 12(5):641-643. PubMed ID: 28580631
    [Abstract] [Full Text] [Related]

  • 12. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J.
    Arthritis Care Res (Hoboken); 2018 Oct 03; 70(10):1536-1540. PubMed ID: 29287309
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 03; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of unresponsiveness to standard high-dose gamma globulin therapy in Kawasaki disease].
    Tavli V, Yilmazer MM, Güven B, Meşe T, Oner T, Demirpençe S.
    Turk Kardiyol Dern Ars; 2010 Jan 03; 38(1):20-4. PubMed ID: 20215838
    [Abstract] [Full Text] [Related]

  • 15. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

  • 17. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 18. ATYPICAL KAWASAKI DISEASE.
    Ristovski L, Milankov O, Vislavski M, Savić R, Bjelica M.
    Med Pregl; 2016 May 17; 69(1-2):53-7. PubMed ID: 27498535
    [Abstract] [Full Text] [Related]

  • 19. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May 17; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 20. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 May 17; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.